Integrative Medicine in Pain Management in Sickle Cell Disease

Pain Clinical Trial

Official title:

Integrative Medicine in Pain Management in Sickle Cell Disease: Assessing the Clinical Efficacy and Neurobiological Impact With Acupuncture

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05045820
• Other study ID #: 10056a
• Secondary ID: 4R00AT010012
• Status: Recruiting
• Phase: N/A
• Start date: June 29, 2021
• Est. completion date: May 31, 2026

Study information

• Verified date: April 2024
• Source: Indiana University
• Contact: Ying Wang, MD, PhD
• Phone: 317-278-5045
• Email: ywa12[@]iu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

Description:

This study will help the investigators to learn whether acupuncture, which is a non-opioid alternative pain management approach, can help to manage pain in patients with sickle cell disease and the underlying mechanisms. Acupuncture involves inserting very fine needles through the skin at specific points on the body to different depths. Acupuncture may help relieve pain and it is used for a wide range of pain conditions. Participation in this study will include 14 study visits over around 6-8 weeks and 12 months follow-up visits. This is a randomized study, which means subjects are randomly assigned to one of two groups. During the study visits: 1) Subjects will be randomized to 10 sessions with either traditional acupuncture (very fine acupuncture needles will be inserted into the skin) or laser acupuncture without needles (a laser acupuncture device will be used and there will be no physical contact between the device and subject's skin) and each session will last for 30 minutes, 2) Subjects will answer questions about their personal and health related information for assessing health condition during the in-person and follow-up study visits, 3) Investigators will perform quantitative sensory testing (QST) before and after the acupuncture sessions on the surface of selected testing areas in subjects to assess the somatosensory functionality, 4) Investigators will record brain signals before and after acupuncture sessions using magnetic resonance imaging (MRI)-an imaging tool to analyze brain structural and functional features and metabolites profile, functional near-infrared spectroscopy (fNIRS)-an imaging tool to examine the brin hemodynamic activity, and electroencephalography (EEG) -an imaging tool used to detect the brain electrical activity, 5) Subjects will receive evoked pain stimuli on the left gastrocnemius muscle during MRI, fNIRS and EEG, 6) Female subjects will take a urine pregnancy test during the screening visit as well as before each behavioral and MRI visit, 7) Investigators will collect an inner eyelid image collection for examining the hemoglobin level and 8) subjects will have two blood draws before and after the entire acupuncture sessions for regular blood examination and circulating biomarkers' analyses.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: May 31, 2026
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 80 Years

Eligibility

Inclusion Criteria:

• Any gender

• 14-17 (Adolescents) and 18-80 (Adults) years old

• Right-handed

• Either outpatient or inpatient or status changing between each other

• Have been diagnosed with SCD (includes but not limited to SS, SC or other type) and experiencing chronic pain in the past 6 months or vaso-occlusive crisis (VOC) in the past 12 months.

• Subjects with ongoing VOC (or hospitalization during enrollment will not be scheduled for QST and MRI sessions, other scheduled sessions will remain.

• Analgesic therapy prescribed by primary hematologists (or physicians for emergency or primary care) including pain-relieving medications (e.g. Morphine, coderin, Fentanyl, Oxycodone), Hydroxyurea (e.g. Droxia, Hydrea, Siklos), L-glutamine oral powder (Endari), Crizanlizumab (Adakveo), Voxelotor (Oxbryta), and/or other palliative treatment allowed, not required.

• Willing to limit the current and the introduction of any new medications or treatment modalities for control of pain symptoms during the study visits.

• Able to travel to the study site for participating scheduled visits (questionnaires, QST, EEG and MRI) and receive acupuncture treatments up to two times weekly for 5 weeks as scheduled.

• We will recruit without regard to ethnicity, however, due to the genetic nature of SCD, subjects will primarily be African-American or of African descent, although there are individuals with SCD who come from Hispanic, southern European, Middle Eastern, or Asian Indian backgrounds. The ethnic distribution in our prior studies is 95% Black/African American with 5% Hispanic or Latino (of any race). As these are minority groups many individuals may be from lower income situations.

• Fluent in English and capable of giving written informed consent.

Exclusion Criteria:

• Subjects with Covid-19 suspicion or confirmation

• Recent/ongoing alternative pain management with acupuncture or acupuncture-related techniques within the last 6-months.

• Presence of a known coagulation abnormality: Thrombocytopenia (mild thrombocytopenia with a platelets range of 51,000-100,000/ul will be further evaluated for inclusion consideration), or bleeding diathesis that may preclude the safe use of acupuncture.

• Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain or any other chronic pain condition with pain greater than sickle pain.

• Diseases/conditions history includes but not limited to:

• head injury with substantial loss of consciousness

• peripheral neuropathy of known cause that interferes with activities of daily living

• known non-SCD related Severe psychiatric illnesses (e.g. current schizophrenia, major depression with suicidal ideation).

• significant visual, motor, or auditory impairment that would interfere with ability to perform study visits-related activities

• Medication:

Recent (30 days) initiation or dose adjustment of stimulant medications, such as those used to treat ADD/ADHD (e.g., amphetamine/dextroamphetamine [Adderall®], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil).

• Contraindications to MRI scans includes but are not limited to: surgical clips, surgical staples, metal implants, cardiac rhythmic disorders, seizure disorders, and certain metallic dental material will not be scheduled for MRI visits.

• History vascular surgery in lower limbs or current lower limb vascular dysfunction will not receive conditioned pressure pain stimuli in the lower limb.

• Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's sickle disease; current involvement in out-of-court settlements for claims pertinent to the subject's sickle disease; or currently receiving monetary compensation as a result of any of the above.

• Participation of other studies: Concurrent participation in other therapeutic trials with overlapping research purposes.

• Pregnant or nursing.

Related Conditions & MeSH terms

• Acupuncture
• Anemia, Sickle Cell
• Electroencephalography
• Functional Near-infrared Spectroscopy
• Magnetic Resonance Imaging
• Pain
• Sickle Cell Disease

Intervention

Procedure:
• acupuncture
Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual "Syndrome" ("reinforce" or "reduce" or "Non reinforce or reduce") that is determined by TCM diagnosis. Acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of treatment which contains 10 treatment sessions.

Other:
• Sham
"Non-Tradition Acupuncture" or a "Placebo Comparator" will be used as sham acupuncture which uses "mock laser" acupuncture approach. Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin. The laser will not be turned on during the treatment. Sham treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of sham treatment which contains 10 treatment sessions.

Locations

Country	Name	City	State
United States	Indiana University School of Medicine	Indianapolis	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
Indiana University	National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

References & Publications (4)

JX Yao, ARW O'Brien, YJ Tong*, Y Wang*. A Novel Finding in Cerebral Blood Flow in Patients with Sickle Cell Disease Using Bold Functional MRI. Blood (2022) 140 (Supplement 1): 5433-5434. (https://doi.org/10.1182/blood-2022-167594)

SM Park, YY Ji, S Kwon, ARW O'Brien, Y Wang*, YL Kim*. Association of Noninvasive Peripheral Blood Hemoglobin Assessments with Venous Blood Draws Among Sickle Cell Patients. Blood (2022) 140 (Supplement 1): 7832-7833. (https://doi.org/10.1182/blood-2022-1

TJ Barrett, A Pucka, B Reyes, SA Jacob, ARW O'Brien, RE Harris, SE Harte, Y Wang*. Acupuncture Alleviates Pain and Improves Quality of Life in Patients with Sickle Cell Disease. Blood. (2022);140 (Supplement 1):5444-5445. (https://doi.org/10.1182/blood-20

Wang Y, Hardy SJ, Ichesco E, Zhang P, Harris RE, Darbari DS. Alteration of grey matter volume is associated with pain and quality of life in children with sickle cell disease. Transl Res. 2022 Feb;240:17-25. doi: 10.1016/j.trsl.2021.08.004. Epub 2021 Aug 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Circulating biomarkers' profile and levels	Circulating biomarkers' expression profile and quantitative level of each targeted biomarker in blood samples will be examined using proteomics, multiplex assays, ELISA and etc.	changes of circulating biomarkers levels from baseline to post-treatment time point (approximately 5 weeks interval)
Other	Blood hemoglobin level	Blood hemoglobin level will be assessed by both regular blood sample analysis and a patented algorithm of spectral super-resolution spectroscopy technique using a software installed smartphone through the participants' inner eyelid.	changes of blood hemoglobin level from baseline to post-treatment time point (approximately 5 weeks interval)
Other	Brain hemodynamic activity	Brain hemodynamic activity will be recorded and examined by functional near-infrared spectroscopy.	changes of brain hemodynamic activity from baseline to post-treatment time point (approximately 5 weeks interval)
Other	Brain structural characteristics	Brain structural features will also be examined using MRI.	changes of brain structural characteristics from baseline to post-treatment time point (approximately 5 weeks interval)
Other	brain electrophysiological characteristics: EEG power in alpha band	Brain electrophysiological signals will be recorded and examined by EEG. EEG power in alpha band will be analyzed using Matlab, EEGLab or other computer software designed for EEG data.	changes of alpha band from baseline to post-treatment time point (approximately 5 weeks interval)
Other	brain electrophysiological characteristics: EEG power in theta band	Brain electrophysiological signals will be recorded and examined by EEG. EEG power in theta band will be analyzed using Matlab, EEGLab or other computer software designed for EEG data.	changes of theta band from baseline to post-treatment time point (approximately 5 weeks interval)
Other	brain electrophysiological characteristics: EEG power in beta band	Brain electrophysiological signals will be recorded and examined by EEG. EEG power in beta band will be analyzed using Matlab, EEGLab or other computer software designed for EEG data.	changes of beta band from baseline to post-treatment time point (approximately 5 weeks interval)
Other	brain electrophysiological characteristics: EEG power in delta band	Brain electrophysiological signals will be recorded and examined by EEG. EEG power in delta band will be analyzed using Matlab, EEGLab or other computer software designed for EEG data.	changes of delta band from baseline to post-treatment time point (approximately 5 weeks interval)
Primary	Functional brain connectivity characteristics	Characteristics of functional brain activity will be studied using fMRI.	changes brain connectivity features from baseline to post-treatment time point (approximately 5 weeks interval)
Primary	Somatosensory function	Somatosensory functionality will be examined using a board tests of which is a reliable and reproducible approach in pain research.	changes of quantitative sensory testing scores from baseline to post-treatment time point (approximately 5 weeks interval)
Primary	Brain metabolites characteristics	Characteristics of brain metabolites will be studied using 1H-MRS.	changes of brain metabolites levels from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	painDETECT Questionnaire	This is 4-component questionnaires that address the location, intensity, quality of pain symptoms. painDETECT is a nine-item questionnaire that consists of seven sensory symptom items for pain that are graded from 0= never to 5= strongly, one temporal item on pain-course pattern graded -1 to +1, and one spatial item on pain radiation graded 0 for no radiation or +2 for radiating pain.	changes of painDETECT scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Brief Pain Inventory (BPI) Questionnaire	A simplified BPI is used to assess the severity of pain, interference of pain on daily function, location of pain, pain medications and amount of pain relief using the rating from 0= no pain/relief/interference to 10= worst pain imaginable/complete relief/completely interferes in the past 24 hours or the past week.	changes of BPI scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Nociplastic Pain Questionnaire	A customized questionnaire that is used to examine the locations (Yes/No) and severity of the pain interference (no problem-slight-moderate--severe) for understanding the level of nociplastic pain in the past 7 days. Widespread Pain Index and Symptom Severity will be scored from 0 to 10. Higher score connotes higher severity of nociplastic pain.	changes of nociplastic scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Hospital Anxiety and Depression Scale (HADS) Questionnaire	HADS is used to determine the levels of anxiety and depression that a person is experiencing in the past one week. The HADS is a fourteen-item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.	changes of HADS scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Psychological Screening Questionnaires (PHQ-9)	PHQ-9 is used to assess the mental health conditions in the past two weeks. Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe, and severe depression, respectively.	changes of PHQ-9 scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Questionnaire	The PROMIS-29 has seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) with customized 29-item questions and a single 0-10 numeric rating for each question.	changes of PROMIS-29 scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Multidimensional Fatigue Inventory (MFI) Questionnaire	MFI is a 20-item self-report instrument designed to measure fatigue with five dimensions including General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Subscale scores (range 4-20) are calculated as the sum of item ratings and a total fatigue score (range 20-100) is calculated as the sum of subscale scores. Higher scores indicate a higher level of fatigue.	changes of MFI scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Pittsburgh Sleep Quality Index (PSQI) Questionnaire	The PSQI is a 19-item, self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.	changes of PSQI scores from baseline to post-treatment time point (approximately 5 weeks interval)
Secondary	Adult Sickle Cell Quality Measure (ASCQ-ME) Questionnaire	ASCQ-Me contains both questionnaires of pain episodes frequency, severity, and the pain impact that can comprehensively examine the disease severity and impact in pain, stiffness, sleep, social function in patients with SCD. Scores for ASCQ-Me impact scales range from 0 to 100, with a standardized SCD population mean of 50 (SD, 10), where lower scores connote worse disease impact.	changes of pain-related quality of life scores from baseline to post-treatment time point (approximately 5 weeks interval), as well as monthly follow-up visits till the 12th month of last in-person visit.
Secondary	Pediatric Quality of Life Inventory (PedsQL, both pediatric and adult versions) Questionnaire	The PedsQL is a self-report and parent-report measure assessing the quality of life in a variety of domains including physical, emotional, social, and school. Items are reverse-scored and transformed to a 0-100 scale where higher scores indicate better quality of life.	changes of pain-related quality of life scores from baseline to post-treatment time point (approximately 5 weeks interval), as well as monthly follow-up visits till the 12th month of last in-person visit.

External Links

•   Indiana CTSI Study Listing